Longevity.Technology

Cellbricks Secures $10M

Berlin‑based Celicks announced a $10 million financing round aimed at accelerating its proprietary 3D bioprinting platform for vascularized tissue implants. The capital will fund the transition of its lead programs from pre‑clinical studies into early‑stage clinical trials, positioning the startup at the forefront of regenerative‑medicine research. Celicks’ technology prints living tissue with built‑in blood‑vessel networks, addressing the long‑standing bottleneck of vascularization that has limited the viability of engineered organs. By creating functional, perfusable constructs, the company hopes to offer an alternative to donor grafts for organs such as kidneys, livers, and endocrine glands, which are critical in both standard and longevity‑focused medicine. The founder emphasized that “functional tissue replacement is a genuine bottleneck in longevity medicine,” noting that even with anti‑aging interventions, organ failure remains inevitable without viable substitutes. Successful vascularization could therefore shift the trajectory of age‑related organ decline and expand therapeutic options beyond scarce donor organs. If Celicks validates its approach in humans, the implications are profound: reduced reliance on organ donation, accelerated drug development pipelines that require human‑like tissue models, and a new market segment for personalized regenerative therapies. Investors and healthcare systems alike will watch closely as the company moves toward clinical validation.